News about Market

Alembic Pharma Wins USFDA Approval for Travoprost Ophthalmic Solution

Alembic Pharmaceuticals has secured USFDA approval for its Travoprost Ophthalmic Solution, with the ANDA deemed therapeutically equivalent to the reference listed drug Travatan Z (0.004%) from Sandoz.

Market | 18/12/2025 | By News Bureau |  127

Senores Pharmaceuticals to Acquire Apnar Pharma and Five ANDAs

Senores Pharmaceuticals has entered into an agreement to acquire 100 percent equity in Apnar Pharma, along with a portfolio of five Abbreviated New Drug Applications (ANDAs), as part of its strategy to expand its footprint in regulated pharmaceutical markets.

Market | 18/12/2025 | By Darshana |  202

Sathgen Therapeutics Expands Global Footprint with US Subsidiary Launch

Sathgen Therapeutics has expanded its global presence with the launch of a US-based subsidiary, appointing Dr Padmaja Ganpathy as Chief Executive Officer and Dr Sendurai Mani as Chief Scientific Officer to lead its next phase of growth and innovation.

Market | 18/12/2025 | By News Bureau |  193

Lupin Secures Positive CHMP Opinion for Ranibizumab Biosimilar

Lupin has received a positive opinion from the CHMP for its ranibizumab biosimilar, supported by comprehensive analytical similarity data and a global Phase III clinical trial involving 600 patients with neovascular Age-related Macular Degeneration (AMD).

Market | 18/12/2025 | By News Bureau |  161

Indian Pharma Exports Rise Over Nine Percent in 2024-25: Government

India’s pharmaceutical exports recorded strong growth in the 2024–25 financial year, increasing by over nine percent to about USD 30.47 billion, according to government data.

Market | 18/12/2025 | By Darshana |  740

INCOG BioPharma Announces USD 200 Million Expansion

INCOG BioPharma has announced a USD 200 million expansion aimed at significantly increasing its injectable drug product manufacturing capacity, with plans to grow its workforce to nearly 1,000 employees at its Fishers campus by 2030.

Market | 17/12/2025 | By News Bureau |  265

Glenmark Secures Exclusive Multi-Region Rights to Aumolertinib from Hansoh Pharma

Glenmark has entered into an exclusive licensing agreement with Hansoh Pharma to commercialise aumolertinib, a third-generation EGFR-TKI approved by the MHRA and China’s NMPA, across multiple international markets, reinforcing the company’s oncology portfolio and expansion strategy in high-growth regions.

Market | 17/12/2025 | By News Bureau |  165

XOMA Royalty to Acquire Generation Bio

The acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna.

Market | 17/12/2025 | By News Bureau |  160

Alphyn Closes USD 25 Million Oversubscribed Series B Financing Round to Advance Dermatology Pipeline

Alphyn has closed an oversubscribed USD 25 million Series B financing round to support its dermatology pipeline, including a global Phase II (b) trial in atopic dermatitis and a Phase II clinical programme in molluscum contagiosum.

Market | 16/12/2025 | By News Bureau |  295

Vor Bio Announces USD 150 Million Private Placement

Vor Bio has announced a private placement expected to raise approximately USD 150 million in gross proceeds before expenses, with the transaction anticipated to close on or about 18 December, 2025, subject to customary closing conditions.

Market | 16/12/2025 | By News Bureau |  145